AstraZenca nabs Pfizer’s top man

TOP Pfizer research executive Martin Mackay has left the world’s biggest drugmaker to head research at rival AstraZeneca as both companies brace for patent expirations on their top-selling medications.

Pfizer will consolidate its research and development under Mikael Dolsten, who had worked with Mackay as co-head of research and development since October in a split of duties created from the company’s $67bn (£46.6bn) merger with Wyeth.

Mackay will take on the new role of president of R&D at London-based AstraZeneca on 1 July.